HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis.

AuthorsD Laszlo, C Rabascio, G Andreola, G Pruneri, V Raia, L Calabrese, D Radice, L Saronni, G Martinelli
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 48 Issue 2 Pg. 437-8 (Feb 2007) ISSN: 1042-8194 [Print] United States
PMID17325914 (Publication Type: Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Chlorambucil
  • Rituximab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 (immunology)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Chlorambucil (administration & dosage)
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Follicular (drug therapy)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: